In non-small-cell lung cancer (NSCLC), EBI3 overexpression and elevated circulating IL-35 levels are linked to advanced disease and poor prognosis [33,34], suggesting IL-35 reflects tumor burden and may facilitate immune evasion. The gene discussed is EBI3; the disease is neoplasm.